Advertisement


Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

ESMO Congress 2022

Advertisement

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Today we are going to talk about the SAMCO-PRODIGE 54 trial, which is a randomized phase two study dedicated to MSI high metastatic colorectal cancer patients that were treated with an PD-L1 called avelumab or a standout second line therapy. All patients have received only one previous line of treatment and we know that immune checkpoint inhibitors are efficient in the SSI high population in first line. However, there is only one randomized data to date and this is the second one dedicated to second line. So altogether 132 patients were recruited, have treated with avelumab have treated with a standard second-line chemotherapy, plus targeted agent, adapted to their rest status as usual. The primary endpoint of the trial was PFS and the patients were stratified for age ... mutation and number of stats. What we have seen in the result is that the primary endpoint is rich PFS is better in patients treated with the immunotherapy than the one treated with chemotherapy with a targeted agent. And what happened is that the curves are crossing several time, so it doesn't allow us to think with medians and as a ratio as usually, but we had to use the Q and chin test that is adapted when the shape of the curves is this way. What we can see also is that some patients are immediately resisting to immunotherapy. Some others are resisting within one year, as it was the case in the keynote 177 first line study, and that when the patients are controlled for several months, they are controlled for a very long period of time with approximately 25 to 30% of the patient controlled for more than two years. In this second line setting where generally overall survival are around one year or less. Concerning tolerability, what we have seen is that avelumab is better tolerated than chemotherapy with have less grade three four toxicities, 30% instead of 50% globally. So it validates the use of an NTP DL-1 or PD-L1 in second line treatment for MSI high colon cancer. However, the primary and secondary resistance occurring during the first care being more important in this trial than in the first line trial. We can say by cross study comparison, but that probably the best. The sooner is the better, and we have to treat this patient as soon as possible. Altogether this is a positive trial that will help us to find a treatment and have scientific data if we see a patient MSI High that has not been previously treated with immunotherapy in second line.

Related Videos

Skin Cancer

Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some cases (Abstract 789O).

Lung Cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Gynecologic Cancers
Immunotherapy

Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression (Abstract 520MO).

 

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Advertisement

Advertisement




Advertisement